Toward calcineurin antagonist minimization [1]

Transplantation

Volumn 77, Issue 1, 2004, Pages 162-

  Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; RAPAMYCIN; STEROID;

ALLOGRAFT; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG USE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LETTER; PRIORITY JOURNAL; PUBLICATION; TRANSPLANTATION;

EID: 1642565978     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000091121.97684.3E     Document Type: Letter

References (5)

1. Stallone G, Di Paolo S, Schena A, et al. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 2003; 75(7): 998-1003.
2. Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777.
3. Kahan BD, for the Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000; 356: 194.
4. Kahan BD, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc 2003; 35: 25S.
5. Mahalati K, Kahan BD. Sirolimus permits steroid withdrawal from a cyclosporine regimen. Transplant Proc 2001; 33: 1270.